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Abstract
Purpose of Review—Despite over a third of the world’s population being chronically infected 
with Toxoplasma gondii, little is known about this largely asymptomatic phase of infection. This 
stage is mediated in vivo by bradyzoites within tissue cysts. The absence of overt symptoms has 
been attributed to the dormancy of bradyzoites. In this review, we reexamine the conventional view 
of chronic toxoplasmosis in light of emerging evidence challenging both the nature of dormancy 
and the consequences of infection in the CNS.
Recent Findings—New and emerging data reveal a previously unrecognized level of 
physiological and replicative capacity of bradyzoites within tissue cysts. These findings have 
emerged in the context of a reexamination of the chronic infection in the brain that correlates with 
changes in neuronal architecture, neurochemistry, and behavior that suggest that the chronic 
infection is not without consequence.
Summary—The emerging data driven by the development of new approaches to study the 
progression of chronic toxoplasma infection reveals significant physiological and replicative 
capacity for what has been viewed as a dormant state. The emergence of bradyzoite and tissue cyst 
biology from what was viewed as a physiological “black box” offers exciting new areas for 
investigation with direct implications on the approaches to drug development targeting this drug-
refractory state. In addition, new insights from studies on the neurobiology on chronic infection 
reveal a complex and dynamic interplay between the parasite, brain microenvironment, and the 
immune response that results in the detente that promotes the life-long persistence of the parasite 
in the host.
Correspondence to: Anthony P. Sinai.
2Present address: Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA, USA
Conflict of Interest Matthew Gentry, Anthony Sinai, Animesh Dhara, Elizabeth Watts, Abhijit Patwardhan, and Robert Murphy 
declare that they have no conflicts of interest.
Compliance of Ethical Standards
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects 
performed by any of the authors.
HHS Public Access
Author manuscript
Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Curr Clin Microbiol Rep. 2016 December ; 3(4): 175–185. doi:10.1007/s40588-016-0045-3.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Toxoplasma; Tissue cyst; Bradyzoite; Glycosylation; CNS infection
Introduction
The transmission of Toxoplasma gondii is mediated by two distinct cyst forms, the oocysts 
formed and shed into the environment by the definitive feline host and the tissue cyst, 
formed within and retained in all infected warm blooded animals [1]. Transmission of tissue 
cysts occurs during the act of carnivory or scavenging of infected tissues. T. gondii acquired 
by either form manifests as an acute infection associated with the rapid replication and 
spread within the body of the host of the tachyzoite form [1, 2]. This phase of infection 
within an immune competent host is typically asymptomatic as proliferating tachyzoites are 
cleared with the mounting of an aggressive innate and acquired immune response. However, 
unlike other infections, clearance of rapidly growing parasites fails to establish a sterile cure 
as a cohort of tachyzoites differentiate into the slow growing bradyzoite form establishing 
themselves within tissue cysts primarily in the CNS and muscle [1, 3]. These tissue cysts are 
maintained for the life of the host, progressing in their cycle during carnivory and 
completing the sexual cycle when the carnivore is a feline [1, 4].
The life-long persistence of tissue cysts and the bradyzoites they house is attributable to their 
relative invisibility to immune detection, a property lost when reactivation to tachyzoites 
occurs [5]. In the absence of immune function, most notably the loss of T cell immunity, as 
occurs in active HIV-AIDS, reactivation of bradyzoites to tachyzoites results in unrestricted 
growth [6]. Untreated active toxoplasmosis typically manifests as toxoplasmic encephalitis, 
on account of the CNS being a primary target for tissue cyst formation. This infection is 
lethal in the context of active HIV-AIDS [7]. Given the high seroprevalence of toxoplasma 
infections in the general human population that approaches 30 % worldwide [8], life-long 
persistence of the agent within tissue cysts represents a potential source of active infection 
following immune suppression [7]. In spite of its critical status in the pathogenesis of 
toxoplasma infections, surprisingly, little work has been done into dissecting bradyzoite and 
tissue cyst biology.
Much of what we know about bradyzoite biology comes from a combination of detailed 
morphological studies [3, 9–13] which reveal the organization of tissue cysts in vivo but 
offer little information on bradyzoite physiology. In contrast, cell culture-based systems have 
focused on the critical transition from tachyzoites to bradyzoites but fail to adequately 
address progression once in the chronic phase [14–16]. Studies focused on the 
transcriptomes of tissue cysts (both in culture and in vivo) by necessity [17, 18•] presented a 
weighted average that masks the behavior of individual tissue cysts and by extension that of 
individual bradyzoites within them. The recurring differences, in cyst burden and size, were 
largely attributed to variations with the host response [19, 20] with little consideration to the 
fact that bradyzoites themselves may be considerably more dynamic than has been 
previously imagined [21••].
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Virtually, all of the functional studies to date, including those assessing the effectiveness of 
drugs, have used the tissue cyst (their numbers and size) as the metric. Inherent in defining 
the tissue cyst rather than the individual bradyzoite within it as the “unit” of the chronic 
phase is the assumption that cysts are largely equivalent and the bradyzoites within them 
uniform with regard to their physiology. The first systematic analysis of bradyzoite 
dynamics within cysts, recently published by our group [21••], directly challenges this 
notion necessitating a reassessment of how we approach understanding chronic 
toxoplasmosis and the development of drugs against this recalcitrant life cycle stage.
Organization of the In Vivo Tissue Cyst
The tissue cyst stage of T. gondii is defined by the elevated level of glycosylation and the 
transformation of the parasitophorous vacuole membrane (PVM) into the tissue cyst wall 
[22]. The cyst wall is 250–500 nm in thickness and is formed from the PVM with a dense 
outer layer sandwiched between the PVM and a more amorphous inner sponge-like layer 
[23]. The tachyzoite intravacuolar network is itself transformed into a meshwork of 
glycosylated proteins and glycolipids which form a filamentous meshwork that is connected 
to the tissue cyst wall [23]. The relative volume occupied by the bradyzoites and this matrix 
varies between cysts [11, 23, 24] and likely contributes to the different hydrodynamic 
densities in Percoll gradients that paradoxically shift from more dense to less dense with the 
progression of the chronic phase [21••].
The cyst wall, clearly evident by electron microscopy, can also be visualized by fluorescence 
microscopy using labeled lectins. Glycosylation in both tachyzoites and tissue cysts is 
evident from spatial distribution of lectin reactivity [25–28]. Lectins binds their target 
glycans with high affinity and specificity [29]. The most prominent staining pattern is that of 
the tissue cyst wall using Dolichos lectin (DBA; recognizing terminal GalNAc) (Fig. 1) [27, 
30, 31]. The primary target being glycosylated with GalNAc, designated TgCST1 [32••], 
was identified by the Weiss group as a high molecular weight mucin that is expressed both 
in tachyzoite vacuoles and tissue cysts, but only substantially glycosylated in the tissue cyst 
form [32••]. Importantly, TgCST1 plays an important structural role as knockout of this gene 
results in extremely fragile cysts that are susceptible to clearance [32••]. Of note, recent 
work from the Weiss laboratory has established that two distinct parasite-encoded 
ppGalNAc-Ts glycosyltransferases glycosylate TgCST1 sequentially and that this 
modification is critical for the structural rigidity of the cyst wall [33].
Insights into machinery associated with glycosylation emerge from the targeted disruption of 
a nucleotide sugar transporter TgNST1 [34•]. Loss of this transporter, the substrate profile of 
which was confirmed experimentally, established that the glycosylation of the cyst wall is 
critical for the persistence of tissue cysts in vivo, despite the absence of any notable defect 
for tachyzoites [34•]. Another important recent development has been the use of unnatural 
sugars that can be chemically modified as tracers to identify novel glycoproteins in the 
parasite without the restrictions imposed by lectin reactivity [35•]. Such approaches can be 
applied to both tachyzoites and bradyzoites to establish glycoproteomes in both life cycle 
stages to better define how glycosylation may impact each of these life cycle stages [35•].
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Examination of the major glycosylation pathways in toxoplasma reveals that the genes 
required to add complex N-linked sugars to proteins are incomplete [36]. In addition, our 
analysis of the genome fails to reveal any genes required for the synthesis or transfer of 
sialic acid (Datta and Sinai unpublished). Yet, lectins directed at complex N-linked sugars 
and sialic acid robustly label tissue cysts suggesting that toxoplasma may actively scavenge 
these sugars from the host cell as a potential mechanism of immune evasion as has been 
proposed [37, 38].
Carbohydrate metabolism plays another vital role in bradyzoite biology as evidenced by the 
earliest electron microscopic studies on tissue cysts in vivo [9, 11, 24], which revealed that 
bradyzoites accumulate amylopectin-like carbohydrate [39, 40]. Amylopectin is a plant 
glucose storage polymer (composed of α1,4-glucose residues with α1,6 linked branch 
points) [41] which has been believed to serve as a ready source of glucose (for energy and 
biosynthesis) upon transmission of cyst to a new host following carnivory [39, 40]. The 
distribution of amylopectin visualized using Schiff staining (Fig. 1) and electron microscopy 
[9] appears to be non-uniform within encysted bradyzoites. Tonkin and colleagues recently 
demonstrated that the Ca2+-dependent protein kinase TgCDPK2 is a key regulator of 
amylopectin metabolism [42••]. Notably, they identified enzymes involved in T. gondii 
amylopectin metabolism that are phosphorylated by TgCDPK2 [42••]. When they ablated 
TgCDPK2, they found massive accumulations of amylopectin in tachyzoites which are 
tolerated [42••]. In contrast, the exaggerated accumulation of amylopectin in bradyzoites 
leads to bradyzoite death [42••]. This strongly suggests that amylopectin levels are tightly 
regulated to ensure homeostasis within the bradyzoite making this pathway a potential target 
for drug development.
Dynamics of Tissue Cyst Burden and Size in Chronic Infection
Most of our knowledge of the chronic phase of toxoplasma infection comes from the murine 
infection and has focused on tissue cysts in the brain. In reality, tissue cysts form in other 
tissues as well, most notably in muscle and other organs [43]. Tissue cysts in muscle are an 
important source of infection of humans from the consumption of raw or undercooked meat 
making it among the most prevalent food borne infections in the USA [44]. Experimental 
studies on chronic toxoplasmosis in muscle are limited [45] although the recent development 
of specific skeletal muscle-based infection systems will undoubtedly accelerate this work 
[46–48].
The focus on chronic toxoplasmosis in the brain stems from the fact that in addition to being 
the primary site of tissue cyst formation, it is also the tissue site where the reactivation of 
cysts drives toxoplasmic encephalitis in the context of immune suppression [6, 7]. On a 
more practical note, the brain is easily recovered intact for histological studies and easily 
homogenized while maintaining the integrity of tissue cysts which can be quantified 
microscopically or purified using Percoll gradients as originally developed [49] and 
subsequently refined [21••]. Studies, to establish the tissue cyst burden in rodents, both mice 
and rats, have been reviewed in detail [50, 51••]. Of note, tissue cyst burdens can vary 
significantly, with these differences impacted by the vertebrate host, host strain, as well as 
the toxoplasma strain being used [24, 51••]. This variability appears to be intrinsic as seen 
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with our experience using the Type II ME49 strain, serially passaged by i.p. injection of 
tissue cysts of infected brain homogenates in inbred female CBA/J mice [21••]. We found 
that, in 99 independent tissue cyst purifications from mouse brains, the average cyst burden 
per mouse could range from under 500 to close to 15,000 cysts [21••]. Cyst numbers, 
particularly at later time points, can be the result of reactivation mediated re-seeding in 
addition to the cysts established at the onset of the chronic infection. This does not appear to 
be the case in rats, where cyst rupture without reactivation occurred frequently [51••] or in 
CBA/J mice where the loss of a cyst was essentially balanced by its apparent replacement, 
implying that vast majority of bradyzoites within the cyst were cleared [21••]. This 
equilibrium appears to be responsible for the average cyst burden remaining relatively stable 
across the 5 time points tested (weeks 3, 4, 5, 6, and 8 post-infection) [21••].
The size of tissue cysts, measured in situ [11, 51••, 52], in homogenized brain tissues [51••, 
53, 54] and following purification in Percoll gradients [21••] has been shown to cover a large 
range from 20 to over 100 microns in diameter. Of note, in rats, tissue cysts rarely reach a 
diameter of 70 microns, and despite variability between toxoplasma strains, no clear pattern 
is observed [51••]. These distributions varied somewhat based on the specimens being 
measured with measurements from histological and electron microscopy tending to be 
smaller than that seen for specimens measured in brain homogenates and following tissue 
cyst purification.
Bradyzoite Replication and Growth Patterns Within Tissue Cysts During 
Chronic Infection
The fact that tissue cysts exhibit heterogeneity in their size suggests that they are dynamic 
growing entities despite being considered largely dormant and metabolically inert. If growth 
is indeed occurring, understanding the behavior of individual bradyzoites within the tissue 
cyst becomes crucial. In the course of imaging Percoll purified tissue cysts, we noted that 
bradyzoites nuclei stained with DAPI or Hoescht dye presented as discrete entities in optical 
sections. We therefore developed a unique imaging protocol and software, BradyCount 1.0 
[21••] to directly enumerate nuclear cross-sections and by extension the number of 
bradyzoites within the widest optical section (diameter) of the tissue cyst. The development 
of BradyCount 1.0 and its implementation revealed that while in general larger tissue cysts 
contained more bradyzoites, this rule did not always hold [21••]. We therefore developed the 
concept of the “packing density” [21••] which quantified the number of bradyzoites within 
the imaged volume as a way to normalize for tissue cyst size. Interestingly, the relationship 
between tissue cyst size and the packing density was found to be an inverse one [21••]. As a 
result, larger tissue cysts contain, in general, proportionately fewer parasites and were 
typically less densely packed, i.e., they contained more matrix between the bradyzoites 
[21••]. The implication of this finding is significant as it conclusively establishes that tissue 
cyst size is not defined by bradyzoite replication. Rather, tissue cysts must expand in order 
for bradyzoites to have the space to replicate into [21••]. Thus, shifts in the packing density 
can be used as an indicator of the recency of bradyzoite replication within the tissue cyst.
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The very notion that bradyzoites can replicate has been the matter of some debate with a 
suggestion that should replication occur within a cyst, it must be due to a bradyzoite 
reverting to tachyzoite for the purpose of dividing [55]. In order to capture bradyzoite 
replication and establish if there were any patterns in replication, we labeled purified tissue 
cysts with an antibody against the inner membrane complex (IMC) component TgIMC3 
[21••]. This protein has the added distinction of being more abundant in the developing 
daughter scaffolds and in recently emerged parasites relative to the gravid mother or other 
more mature parasites [56]. Furthermore, the Gubbels group established that TgIMC3 levels 
in the mother decrease over time unless a fresh round of replication is initiated [56] (Fig. 2). 
This provides for an internal marker of the recency of replication as “younger parasites” 
label more brightly for TgIMC3 than “aged” organisms. When examining tissue cysts for 
evidence of bradyzoite replication, we were able to capture evidence for replication at all 
time points tested [21••]. Somewhat surprisingly, distinct patterns of replication within tissue 
cysts emerged as well [21••]. As seen in Fig. 2, evidence of sporadic and clustered and even 
completely synchronized replication were all observed. The frequent detection of clustered 
replication that can extend to synchronous replication (a feature of tachyzoite replication 
within a vacuole) within a tissue cyst argues for a high level of coordination and signaling 
among bradyzoites within a cyst. Furthermore, this suggests that bradyzoites within a tissue 
cyst are heterogenous and not monolithic physiological entities [21••] as they have been 
assumed to be.
The likelihood of capturing replicating parasites was found to vary depending on the specific 
state of the infection [21••]. In contrast to tachyzoites within a vacuole, bradyzoites within 
tissue cysts are heterogenous with regard to their replicative potential and physiology [21••]. 
This greatly complicates the dissection of the chronic phase even though it progresses 
toward dormancy [21••]; its path to this state appears to be opportunistic and exhibits 
oscillatory behavior [21••] with a pattern suggestive of punctuated and potentially cyclical 
growth profiles evident both at the level of individual bradyzoites within tissue cysts at the 
population as a whole [21••]. The development of tools to address the behavior of individual 
bradyzoites within cysts such as BradyCount 1.0 together with ongoing development 
permitting quantitative measurement of other structural and physiological outputs 
(BradyCount 2.0, Patwardhan and Sinai, in progress) will greatly expand the range of 
measurable activities to gain new insights into bradyzoite biology. Given the nature of these 
studies where we are constrained by practical limitations regarding the amount of data that 
can be acquired, we are developing data-driven computational models to better understand 
the complex and understudied progression of chronic toxoplasmosis (Patwardhan and Sinai, 
in progress). The heterogeneity in bradyzoite replication and other physiological parameters 
[21••] suggests an opportunistic phenomenon that is not substantially affected by the events 
preceding it. Rather the behavior of a given bradyzoite within a tissue cyst or a population of 
tissue cysts within an animal is dominated by the specific physiological state (or distribution 
of physiological states—if examining the population) at the time of capture. This structure is 
less reliant on memory and lends itself to a Markov Chain model. Such models will be of 
great value to establish the mechanisms of both drug susceptibility and inherent resistance 
(see below).
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How the dynamics of the chronic infection influences the host is as fascinating a question as 
to how the host status influences the progression of the chronic phase within the host. The 
first insights into how the presence of a chronic infection within the brain impacts gene 
expression in the brain has emerged from a deep sequencing RNA Seq study from the Knoll 
laboratory [18•]. Using the depth of RNA Seq and simultaneously profiling both the host 
and parasite transcriptomes, they establish that despite the absence of any symptoms or other 
evidence of the presence of the parasite dramatic changes in the expression of genes, 
including those involved in inflammation and immune responses, are observed [18•]. 
Notably, on the parasite side of the equation, expression of genes associated with an active 
cell cycle indicates that our notions of dormancy need to be reexamined [18•]. Thus, as 
regards the chronic infection in the brain, a dynamic picture emerges that is defined by 
bidirectional effects between the parasite and the host. Exciting new findings in the area are 
emerging against the backdrop of understanding the neurobiology of chronic infection.
Emerging Insights into Neurobiology of Chronic Toxoplasma Infection
With its long-term, potentially lifelong residence in the brains of healthy individuals and 
animals without any significant clinical consequence, chronic toxoplasma infection has been 
viewed as a benign condition. This absence of overt symptomology has contributed to the 
view that tissue cysts and the bradyzoites they house are dormant entities.
Recent developments in neurology, behavior, and neuroscience directly challenge the notion 
that chronic toxoplasma infections are without consequence. An emerging body of evidence 
suggests that the presence of an established chronic infection may contribute to the 
pathogenesis of diverse neurological conditions including schizophrenia [57, 58], epilepsy 
[59], and neurodegenerative conditions [60–62]. These studies and their impact on our 
understanding of chronic toxoplasmosis in human disease are reviewed elsewhere [57, 59, 
60, 62]. In addition, evidence from rodent studies suggests that the chronic toxoplasmosis 
results in the modulation of the host’s behavior (reviewed in [63, 64]). These studies which 
have received considerable traction in the popular press are also discussed in several recent 
reviews and may have parallels in affecting human behavior as well [65].
The diverse spectrum of neurological and behavioral changes suggests that chronic 
toxoplasma infection in the brain does in fact manifest changes reinforcing the notion that 
these parasites are not truly dormant or latent. Recent studies have now begun to unveil the 
potential mechanistic insights into the neurobiology of chronic toxoplasmosis. These 
findings represent the first meaningful mechanistic steps into this complex interdisciplinary 
area that promises to be fertile area for investigation. As a cautionary note, care must be 
taken to try and untangle the effects that are a direct consequence of the parasite from those 
that are driven by persistent low level inflammation in the infected brain [18•, 66].
The spectrum of neurological and behavioral changes associated with chronic toxoplasmosis 
would suggest that the spatial distribution of cysts (which may number in the thousands, but 
still represent a miniscule number relative to the cellularity of the brain) may govern the 
phenotypic consequence [63]. While some mapping studies suggested the concentration of 
cysts in the amygdala [67] and hippocampus [68], others failed to find a strong association 
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for this or any other site [51••, 69–71]. Some controversy also exists with regard to the 
specific cells within the brain being infected and able to house developing cysts. While there 
is agreement that neurons are likely to be the primary host cell of relevance [72–74], 
infection of microglia and astrocytes [73, 74] may also contribute as potential sites for tissue 
cyst formation.
The first studies on the neurochemistry of chronic toxoplasmosis are now emerging and 
reveal that the presence of the parasite drives changes in the levels of neurotransmitters, their 
precursors, and metabolites. Among the potential direct mechanisms for the modulation of 
neuronal action is the injection of primarily rhoptry derived host effector proteins (see 
reviewed in [75]) into both cells that the parasites invade as well as cells they interact with 
without invading [76, 77]. In this way, the parasite can directly influence not only the cell it 
infects but others in their vicinity.
The perturbation of dopamine, a neurotransmitter associated with several neurodegenerative 
and psychiatric conditions [78], is intriguing given that toxoplasma encodes and expresses a 
secreted tyrosine hydroxylase, a key enzyme in dopamine metabolism [79•, 80]. This 
presents the potential for direct manipulation of infected neurons as infected neurons release 
3-fold higher levels of dopamine upon stimulation [80].
The effect of toxoplasma infection extends to gamma aminobutyric acid (GABA) synapses 
and signaling. GABA is a metabolite used by the parasite and is also an inhibitory 
neurotransmitter important in epilepsy. The Blader laboratory showed that, in the course of 
T. gondii infection, the redistribution (but not change in levels of) of synaptic glutamic acid 
decarboxylase 67 (GAD67) is associated with the development of seizures [81•]. Notably, 
the duration and severity of seizures triggered by GABA agonists were dependent on the 
infecting parasite strain arguing against a generalized effect caused by infection or 
inflammation [81•].
Toxoplasma effectively disrupts glutamate homeostasis in the infected brain [82••]. This is 
achieved by the selective downregulation of the primary astrocyte glutamate transporter 
GLT1 [82••]. Astrocytes serve as a critical buffer to clear extracellular glutamate which is 
neurotoxic and drives changes in neuronal architecture and morphology that interfere with 
efficient neuronal function [83]. The Wilson group, in a recent study, functionally 
demonstrated using microdialysis of the murine frontal cortex that levels of free glutamate 
were higher in the infected brain over the course of infection [82••]. While the specific 
molecular mechanism and parasite are not known, the finding that neuronal dysregulation in 
chronic toxoplasma infections can be driven by an effect on astrocyte functions reveals that 
this dysregulation is as sophisticated as it is complex.
Adding to the complexity of the pathogen-host relationship in the brain is the progression of 
the host immune response during the course of the infection (reviewed in [84]) which is 
beyond the scope of the current article.
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Therapeutic Targeting of Chronic Toxoplasma Infections
Virtually, all studies to date to examine the effects of drugs against chronic toxoplasma 
infections have used the elimination of tissue cysts as the primary metric for efficacy. This is 
a relatively crude measure as it does not address the effect on the level of individual 
bradyzoites, their organization within cysts, and by extension their physiological state/
replication potential. Given the heterogeneity of bradyzoites within tissue cysts and the 
diversity of tissue cysts within the infected brain [21••], the dissection of drug effects needs 
to be achieved at the level of bradyzoites. The imaging approached provided by BradyCount 
1.0 allows for the direct enumeration of bradyzoites within cysts and insights into tissue cyst 
organization based on the computed packing density [21••]. The ongoing expansion of the 
capabilities in BradyCount 2.0 (Patwardhan and Sinai, in progress) will allow for more 
refined data regarding quantifiable physiological criteria that can serve as inputs for data-
driven computational models.
The clinical management of toxoplasmosis relies on the targeting of actively growing 
tachyzoites [85, 86]. The primary drug combination targets folate metabolism on account of 
the synergizing activities of pyrimethamine and sulfadiazine targeting dihydrofolate 
reductase (DHFR) and dihydropterate synthase (DHPS), respectively [87]. Tissue cysts and 
bradyzoites within them appear refractory to these antifolate drugs likely due to the low level 
of DNA synthesis in the overall cyst population. The direct of demonstration of active 
bradyzoite replication within in vivo tissue cysts [21••] suggests that this subpopulation of 
bradyzoites should be susceptible. Just such an effect on bradyzoites is suggested by the 
reduction of genome equivalents in the presence of Pyr/Sulfa in vivo using quantitative PCR 
in infected brain samples [88].
The earliest indication of drug capable of reducing the tissue cyst burden was observed in 
the case of atovaquone [89–91]. This drug targets mitochondrial respiration at the level of 
the cytochrome bc1complex [92]. More recently, the endochin-like quinolones, which also 
target mitochondrial respiration were found to eliminate tissue cysts at between 76 and 88 % 
of the control, levels far greater than those achieved with atovaquone [93••]. That 
mitochondrial respiration targeting drugs appear to be effective suggests that mitochondrial 
respiration must play a role in the maintenance of the chronic state thereby providing a 
measurable physiological parameter for analysis. Other classes of drugs including 
guanabenz, an FDA-approved drug targeting translational control through eIF2α [94], both 
reduce the number of cysts formed when administered during the acute phase while also 
promoting a reduction in the cyst burden during the chronic phase [95•]. Finally, a recently 
developed inhibitor of the calcium-dependent protein kinase 1 (TgCDPK1) has also shown 
promise in reducing the cyst burden [96•] by levels similar to what was observed with the 
endochin-like quinolones [93••]. Importantly, unlike the encochin-like quinolones [93••], the 
TgCDPK1-directed compounds are effective with oral administration [96•]. Furthermore, the 
bradyzoite specific lethality associated with the TgCDPK2 knock-out [42••] presents this 
kinase and amylopectin metabolism as a legitimate drug target.
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These recent developments, identifying multiple potential druggable targets coupled with an 
emerging appreciation for bradyzoite replication and physiology, point toward a new phase 
in the development of drugs targeting chronic toxoplasmosis.
Conclusions
A convergence of recent studies directly addressing the progression of chronic 
toxoplasmosis in vivo, advances in the neurobiology of infection, and the identification of 
new and effective drug targets presents new opportunities to understand this poorly studied 
though critical life cycle stage of the parasite. Thus, the study of tissue cyst and bradyzoite 
biology is emerging from the shadows where the area was treated largely as black box. The 
field is poised to exploit new technological developments in parasite molecular and cell 
biology to take on challenging questions at a level of sophistication that was unimaginable 
even a few years ago. Understanding the basis of bradyzoite physiology and metabolism in 
the context of both the immune competent and immune suppressed host will accelerate the 
development of much needed therapies.
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Fig. 1. 
Distribution of key glycans in tissue cysts. A distinguishing feature of Toxoplasma gondii 
tissue cysts is the high level of glycosylation. Left panel lectin staining with FITC-
conjugated Dolichos biflorus (DBA-recognizing GalNAc) lectin labels the tissue cyst wall 
and the intra-cyst matrix (green). In contrast, Concanavalin A (ConA-recognizing mannose 
and glucose, and an indicator of N-linked glycosylation) selectively stains structures within 
the bradyzoites and in the matrix (red) but is excluded from the tissue cyst wall (merge). 
Right panel the distribution of amylopectin granules within bradyzoites detected using 
Schiff reagent (red) overlaid on a differential interference contrast of a purified tissue cyst 
reveals an uneven distribution of amylopectin within the tissue cyst with clusters of 
bradyzoites exhibiting high levels of amylopectin (outlined in green) adjacent to areas with 
low amylopectin levels (outlined in yellow)
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Fig. 2. 
Evidence of replication and patterns of replication within tissue cysts. Tissue cysts and the 
bradyzoites within them have been viewed as dormant non-replicative entities. Replication 
by endodyogeny and cytokinesis in toxoplasma can be detected using antibodies against 
components of the inner membrane complex (IMC) including TgIMC3. Top panel the 
intensity of TgIMC3 is highest in developing daughter parasites and recently emerged 
parasites. Following emergence, the TgIMC3 signal loses intensity and can thus serve as a 
marker for the recency of replication. Bottom panel actively replicating bradyzoites within 
tissue cysts can be detected based on the level of TgIMC3 labeling. Evidence for sporadic 
replication (left panel, arrowheads), clustered replication (outlined in yellow) with a region 
where replication is not occurring (outlined in red) are seen in most cases. In several cases, 
highly synchronized replication whereby all the bradyzoites within tissue cyst were dividing 
at the same time is observed. Together, these findings suggest that the tissue cysts are 
dynamic entities containing replication competent bradyzoites
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